Currently Recruiting: Bristol-Myers Squibb study/ Primary Sjogren's

[quietdynamics]

Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
https://clinicaltrials.gov/show/NCT02843659

At a glance
Originator Bristol-Myers Squibb
Class Monoclonal antibodies; Polyethylene glycols
Mechanism of Action CD28 antigen modulators; Immunosuppressants
Orphan Drug Status No
On Fast track No
New Molecular Entity No
Highest Development Phases

Phase II Sjogren's syndrome; Systemic lupus erythematosus

03 Mar 2017 Bristol Meyers Squibb plans a phase I trial in Healthy volunteers in USA (NCT03058822)
https://clinicaltrials.gov/ct2/show/NCT03058822
01 Oct 2016 Phase-II clinical trials in Sjogren's syndrome in USA (SC) (NCT02843659)
21 Jul 2016 Bristol-Myers Squibb plans a phase II trial for Sjögren's syndrome in Australia, Chile, Hungary, Mexico, Poland, Puerto Rico, Russia and South Africa and USA (SC, Injection) (NCT02843659)

"..compound lulizumab pegol (BMS-931699), which targets the T-cell-specific surface glycoprotein CD28.."
http://www.genengnews.com/gen-news-highlights/bms-licenses-autoimmune-research-program-from-novo-nordisk/81251062

A monovalent anti-human CD28 domain antibody antagonist: preclinical efficacy and safety.  https://www.ncbi.nlm.nih.gov/pubmed/24081989

I tried to follow timeline. Appears drug compounds where initially began for mild to severe Rheumatic patients, for whom MTX was not adequate. Studies began on SLE and SJS.